Benyam Muluneh
Overview
Explore the profile of Benyam Muluneh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Muluneh B, Li Q, Hughes J
Clin Cancer Res
. 2025 Feb;
PMID: 40013954
Patient reported outcome (PRO) plays a crucial role as clinical endpoint in oncology trials. Traditional statistical methods, such as hypothesis testing, have been commonly used by pharmaceutical industry and regulators...
2.
Muluneh B, Upchurch M, Mackler E, Bryant A, Wood W, Wheeler S, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996877
Clinical trials inform cancer care, yet real-world outcomes often diverge due to patient-related factors, like age, organ dysfunction, and nonadherence to oral anticancer agents (OAAs). While oncology organizations emphasize patient...
3.
Muluneh B, Upchurch M, Belayneh B, Mackler E, Bryant A, Wood W, et al.
Res Social Adm Pharm
. 2025 Feb;
21(6):444-452.
PMID: 39988489
Background: The increasing use of targeted oral anticancer agents (OAAs) has transformed cancer treatment, yet patient adherence in real-world settings remains suboptimal. This protocol outlines a multi-phasic, hybrid effectiveness-implementation trial...
4.
Nachar V, Adams Curry M, Kostoff D, Wood A, Farris K, Muluneh B, et al.
JCO Oncol Pract
. 2025 Jan;
OP2400475.
PMID: 39847731
Purpose: The Hematology Oncology Pharmacist Association Oral Chemotherapy Collaborative (HOPA OCC) developed practice-based tools to use in program development and improvement for the management of patients receiving oral anticancer agents...
5.
Lee J, Beers J, Cheng I, Truong V, Brown Z, Muluneh B, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70106.
PMID: 39673246
Venetoclax is a first-in-class orally administered B-cell lymphoma-2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its...
6.
Stover A, Liang D, Mueller D, Kurtzman R, Ikemeh C, Canter C, et al.
Qual Life Res
. 2024 Oct;
34(1):201-217.
PMID: 39404983
Purpose: Patient reported outcome measures (PROMs) are increasingly used in oncology care, but pharmacists providing direct patient care have been overlooked. We engaged pharmacists and adults receiving oral oncolytics (chemotherapy...
7.
Maas M, Yang A, Muir M, Collins 4th J, Canter C, Tamamyan G, et al.
Cancer Med
. 2024 Sep;
13(17):e70125.
PMID: 39248149
Purpose: Cancer is a leading cause of global childhood mortality, affecting 400,000 children annually. While treatable with modern therapies, children living in low- and middle-income countries (LMICs) have limited access...
8.
Webb N, Matys S, Collins J, Garcia J, Worku K, Lines M, et al.
J Oncol Pharm Pract
. 2024 May;
:10781552241249420.
PMID: 38695136
Introduction: The increasing incidence of cancer and capacity for cancer care in Ethiopia has led to an upsurge in chemotherapy use in the country; however, studies indicate that there is...
9.
Upchurch M, Muluneh B
Expert Rev Clin Pharmacol
. 2024 Apr;
17(5-6):467-475.
PMID: 38629382
Introduction: There has been a paradigm shift in the treatment of chronic lymphocytic leukemia (CLL) over the past decade. With the advent of self-administered targeted oral anticancer agents (OAAs), the...
10.
Asfaw S, Matys S, Muluneh B
Clin J Oncol Nurs
. 2024 Mar;
28(2):215-219.
PMID: 38511918
Although the field of oncology pharmacotherapy has progressed rapidly with the introduction of novel targeted therapies, there are many unintended side effects that require knowledge of laboratory monitoring for appropriate...